On Thursday’s episode of Mad Money, host Jim Cramer highlighted several of the top-performing stocks of the day within the S&P 500.
“For much of the tremendous run over the past decade, critics love to point out that most of our gains were coming from a small cadre of tech stocks… Over and over again, as the market roared higher, we were told that the rally was so narrow that it could not be sustainable.”
READ ALSO 13 Stocks Jim Cramer Recently Shed Light On and 11 Stocks Jim Cramer Put Under the Microscope Recently
However, Cramer pushed back against that narrative. He mentioned that if investors are actively engaged, constantly analyzing what fails, what risks exist, and what opportunities are real, they can start to see that markets do not always behave as critics expect.
Whilst he did admit that narrow rallies can collapse under their own weight, he pointed out that that is not the only outcome. He mentioned that they can also begin to include a wider range of sectors and companies, which would push the market to new highs without including those who were bearish on the rally.
“Here’s the bottom line: For years, we were warned that our rallies were too narrow. Now, we’ve got a broad leadership group. Today, it was a solar, a couple of minerals, a crypto platform, two data center stocks, a utility, a biotech, and a natural gas producer. That’s what I call a real broad, bullish rally. Everyone who warned you that the market was too narrow to go higher is now either closing out their short positions or getting their faces ripped off. Neither’s a good thing.”
Our Methodology
For this article, we compiled a list of 10 stocks that were discussed by Jim Cramer during the episodes of Mad Money aired on June 26. We listed the stocks in the order that Cramer mentioned them. We also provided hedge fund sentiment for each stock as of the first quarter of 2025, which was taken from Insider Monkey’s database of 1,000 hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
Jim Cramer Highlighted the Top 10 S&P 500 Winners of the Day
10. APA Corporation (NASDAQ:APA)
Number of Hedge Fund Holders: 42
APA Corporation (NASDAQ:APA) is one of the top 10 S&P 500 winners of the day that Jim Cramer highlighted. During the episode, Cramer commented that the stock is cheap as compared to its assets, as he said:
“Finally rounding things out… APA, the old Apache, [it] can run, but they can’t hide. This is an oil and gas company, primarily natural gas. Apache’s been a huge disappointment over the years. Maybe now that it’s APA, it won’t be. Well, anyway, maybe M&A’s picking up.
I had to wonder whether there’s something going on here because otherwise it shouldn’t be going up. I still prefer Coterra for natural gas. Still, no denying that Apache’s cheap versus its assets, and no denying that it’s not a tech company.”
APA (NASDAQ:APA) is an independent energy company engaged in the exploration, development, and production of natural gas, crude oil, and natural gas liquids, with additional global exploration and project interests.
9. Incyte Corporation (NASDAQ:INCY)
Number of Hedge Fund Holders: 37
Incyte Corporation (NASDAQ:INCY) is one of the top 10 S&P 500 winners of the day that Jim Cramer highlighted. Cramer appreciated the new CEO of the company, as he commented:
“We then have Incyte. That’s a biotech company. It just got a new CEO, Bill Meury. He’s an industry veteran, known as a deal maker. Makes sense. Meury was previously the CEO of Karuna Therapeutics, which he sold to Bristol Myers for a very nice premium, that better start working soon. Before that, he was… [the] chief commercial officer at Allergan. It’s a company famous for its deal-making.”
Incyte (NASDAQ:INCY) is a biopharmaceutical company that focuses on developing and commercializing therapies for cancer, inflammatory conditions, and rare diseases. The company provides a range of approved drugs and advances a diverse pipeline of clinical-stage candidates. On June 26, the company announced that its CEO of 11 years, Hervé Hoppenot, retired and was succeeded by the industry leader Bill Meury.
On the same day, RBC noted that Meury’s background in leading major biotech deals has raised some investor speculation about it becoming a potential M&A target. Nevertheless, Incyte’s position as a commercial-stage company and the expected loss of Jakafi exclusivity, which could cut earnings by 76% by the end of the decade, may limit that potential. RBC sees Meury’s experience as a positive for the company’s future and kept a Sector Perform rating with a $67 price target on the stock.